XML 48 R40.htm IDEA: XBRL DOCUMENT
v3.19.3

Royalty Purchase Agreements (Details) |  |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 26, 2019 USD ($) | Apr. 07, 2019 USD ($) | Feb. 25, 2019 USD ($) Agreement | Sep. 20, 2018 USD ($) LicensedProduct | Sep. 30, 2019 USD ($) | Sep. 30, 2019 USD ($) | Sep. 30, 2019 USD ($) | Dec. 31, 2018 USD ($)
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Long-term royalty receivables |  |  |  |  | $ 34,375,000 | $ 34,375,000 | $ 34,375,000 | $ 15,000,000 | [1]
Changes in estimated fair value of contingent consideration |  |  |  |  |  |  | 0 |  |
Payments of contingent consideration |  |  |  |  |  | 0 |  |  |
Royalty Purchase Agreement [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Long-term royalty receivables |  |  |  |  | 34,375,000 | 34,375,000 | 34,375,000 | 15,000,000 |
Impairment related to long-term royalty receivable |  |  |  |  |  |  | 0 |  |
Royalty Purchase Agreement [Member] | Agenus [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Payments to acquire milestones and royalties |  |  |  |  |  |  | 15,000,000 |  |
Long-term royalty receivables |  |  |  |  | 15,000,000 | 15,000,000 | 15,000,000 | 15,000,000 |
Impairment related to long-term royalty receivable |  |  |  |  |  |  | 0 | $ 0 |
Royalty Purchase Agreement [Member] | Agenus [Member] | Silicon Valley Bank [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Loan borrowed |  |  |  |  | 7,500,000 | 7,500,000 | 7,500,000 |  |
Royalty Purchase Agreement [Member] | Agenus [Member] | Incyte [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Number of licensed products related to milestone and royalties | LicensedProduct |  |  |  | 6 |  |  |  |  |
Royalty Purchase Agreement [Member] | Agenus [Member] | Merck [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Number of licensed products related to milestone and royalties | LicensedProduct |  |  |  | 1 |  |  |  |  |
Royalty Purchase Agreement [Member] | Agenus [Member] | Incyte and Merck [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones |  |  |  | $ 59,500,000 |  |  |  |  |
Royalty Purchase Agreement [Member] | Agenus [Member] | Right to Receive Low-Single Mid-Teen Royalties [Member] | Incyte [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Purchased percentage of royalties on net sales of products |  |  |  | 33.00% |  |  |  |  |
Purchased percentage of milestones |  |  |  | 10.00% |  |  |  |  |
Royalty Purchase Agreement [Member] | Agenus [Member] | Right to Receive Low Single Digit Royalties [Member] | Merck [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Purchased percentage of royalties on net sales of products |  |  |  | 33.00% |  |  |  |  |
Purchased percentage of milestones |  |  |  | 10.00% |  |  |  |  |
Royalty Purchase Agreement [Member] | Bioasis Technologies Inc [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Payments to acquire milestones and royalties |  |  |  |  |  |  | 300,000 |  |
Long-term royalty receivables |  |  | $ 400,000 |  |  |  |  |  |
Impairment related to long-term royalty receivable |  |  |  |  |  |  | 0 |  |
Percentage of Option to purchase royalty right on future license agreements |  |  | 1.00% |  |  |  |  |  |
Number of license agreements | Agreement |  |  | 2 |  |  |  |  |  |
Estimated fair value of contingent consideration |  |  |  |  | 100,000 | 100,000 | 100,000 |  |
Royalty Purchase Agreement [Member] | Bioasis Technologies Inc [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Potential future cash payments |  |  |  |  | 200,000 | $ 200,000 | $ 200,000 |  |
Royalty Purchase Agreement [Member] | Aronora [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Long-term royalty receivables |  | $ 9,000,000 |  |  |  |  |  |  |
Potential future cash payments |  | 3,000,000 |  |  |  |  |  |  |
Payments of contingent consideration |  | $ 3,000,000 |  |  | $ 3,000,000 |  |  |  |
Expected reduction in purchased percentage of non-royalties on net sales of products |  | 5.00% |  |  |  |  |  |  |
Upfront payment |  | $ 6,000,000 |  |  |  |  |  |  |
Milestones payments to aggregate amount of per product |  | 85,000,000 |  |  |  |  |  |  |
Received cumulative royalties on net sales per product amount |  | 250,000,000 |  |  |  |  |  |  |
Royalty Purchase Agreement [Member] | Aronora [Member] | Term Loan [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Upfront payment |  | 3,000,000 |  |  |  |  |  |  |
Royalty Purchase Agreement [Member] | Aronora [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Potential future cash payments |  | $ 1,000,000 |  |  |  |  |  |  |
Royalty Purchase Agreement [Member] | Aronora [Member] | Bayer Products [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Purchased percentage of royalties on net sales of products |  | 100.00% |  |  |  |  |  |  |
Purchased percentage of non-royalties on net sales of products |  | 10.00% |  |  |  |  |  |  |
Royalty Purchase Agreement [Member] | Aronora [Member] | Non-Bayer Products [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Purchased percentage of non-royalties on net sales of products |  | 10.00% |  |  |  |  |  |  |
Royalty Purchase Agreement [Member] | Palobiofarma, S.L {Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Payments to acquire milestones and royalties | $ 10,000,000 |  |  |  |  |  |  |  |
Long-term royalty receivables | 10,000,000 |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Member] | Palobiofarma, S.L {Member] | Silicon Valley Bank [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Loan borrowed | $ 5,000,000 |  |  |  |  |  |  |  |
Royalty Purchase Second License Agreement [Member] | Bioasis Technologies Inc [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Obligation upon exercise of options per licensed product |  |  | $ 300,000 |  |  |  |  |  |
Royalty Purchase Third License Agreement [Member] | Bioasis Technologies Inc [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |
Royalty Purchase Agreement [Line Items] |  |  |  |  |  |  |  |  |
Obligation upon exercise of options per licensed product |  |  | $ 400,000 |  |  |  |  |  |
[1] | The consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

X
- Definition Changes in estimated fair value of contingent consideration. + References No definition available. + Details
Name: | xoma_ChangesInEstimatedFairValueOfContingentConsideration
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contingent future cash payments. + References No definition available. + Details
Name: | xoma_ContingentFutureCashPayments
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Contractual obligation estimated fair value of contingent consideration liability. + References No definition available. + Details
Name: | xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Expected reduction in purchased percentage of non-royalties on net sales of products. + References No definition available. + Details
Name: | xoma_ExpectedReductionInPurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The aggregate amount of write-downs for impairments recognized during the period related to long term royalty receivable assets. + References No definition available. + Details
Name: | xoma_ImpairmentOfLongTermRoyaltyReceivable
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Loan borrowed. + References No definition available. + Details
Name: | xoma_LoanBorrowed
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Long-term royalty receivable non current. + References No definition available. + Details
Name: | xoma_LongTermRoyaltyReceivableNonCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestones payments to aggregate amount of per product. + References No definition available. + Details
Name: | xoma_MilestonesPaymentsToAggregateAmountOfPerProduct
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of future license agreements under optional purchase right. + References No definition available. + Details
Name: | xoma_NumberOfLicenseAgreements
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of licensed products related to milestones and royalties purchased. + References No definition available. + Details
Name: | xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payments of contingent consideration. + References No definition available. + Details
Name: | xoma_PaymentsOfContingentConsideration
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments to acquire milestones and royalties. + References No definition available. + Details
Name: | xoma_PaymentsToAcquireMilestonesAndRoyalties
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments to be made upon exercise of option. + References No definition available. + Details
Name: | xoma_PaymentsToBeMadeUponExerciseOfOption
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percentage of optional royalty rights purchase on future license agreements. + References No definition available. + Details
Name: | xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Purchased eligible milestone payments receivable upon achievement of potential development regulatory and commercial milestones. + References No definition available. + Details
Name: | xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Purchased percentage of milestones. + References No definition available. + Details
Name: | xoma_PurchasedPercentageOfMilestones
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Purchased percentage of non-royalties on net sales of products. + References No definition available. + Details
Name: | xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Purchased percentage of royalties on net sales of products. + References No definition available. + Details
Name: | xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Received cumulative royalties on net sales per Product amount. + References No definition available. + Details
Name: | xoma_ReceivedCumulativeRoyaltiesOnNetSalesPerProductAmount
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty purchase agreement. + References No definition available. + Details
Name: | xoma_RoyaltyPurchaseAgreementLineItems
Namespace Prefix: | xoma_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment. + References No definition available. + Details
Name: | xoma_UpfrontPayment
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_AgenusIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LineOfCreditFacilityAxis=xoma_SiliconValleyBankMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=xoma_IncyteEuropeSarlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=xoma_MerckSharpAndDohmeCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=xoma_IncyteEuropeSarlAndMerckSharpAndDohmeCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_RightToReceiveLowSingleToMidTeenDigitRoyaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_RightToReceiveLowSingleDigitRoyaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_AronoraIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=xoma_TermLoanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_BayerProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_NonBayerProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_PalobiofarmaSLMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseSecondLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseThirdLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |